CTLT
$38.22
Catalent
$.28
.74%
CTLT
Earnings Whisper ®
N/A
2nd Quarter December 2018
Consensus:  $0.33
Revenue:  $617.44 Mil
Tuesday
Feb 5
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, November 6, 2018

What do you expect when CTLT reports earnings?
Beat
Meet
Miss

Where is CTLT's stock price going from here?
Up
Flat
Down
Stock chart of CTLT
Analysts
Summary of analysts' recommendations for CTLT
Score
Grade
Pivots
Resistance
$39.51
$39.11
$38.67

$38.27

Support
$37.83
$37.43
$36.99
Tweet
Growth
Description
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey.
Peers
Vertex PharmaceuticalsCelgeneRegeneron PharmaceuticalsBioMarin PharmaceuticalEndo International plcUltragenyx PharmaceuticalMylanZoetisAlkermesInterCept